Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 11/20 | 0.83 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.53 |
| ▸ | NAMPT | P43490 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13873300 | 0.91 | EPHX2 (1.00) | EPHX2ALDH1A1HRH3POLBKDM4E | |
| SCHEMBL13873295 | 0.88 | EPHX2 (0.81) | EPHX2ALDH1A1HRH3POLBKDM4E | |
| SCHEMBL14413648 | 0.87 | EPHX2 (0.64) | EPHX2ALDH1A1NAMPTCYP2C9CYP2C19 | |
| SCHEMBL13873418 | 0.81 | EPHX2 (1.00) | EPHX2ALDH1A1HRH3POLBKDM4E | |
| SCHEMBL13623458 | 0.79 | EPHX2 (0.84) | EPHX2ALDH1A1POLBKDM4ECYP2C9 | |
| SCHEMBL14413643 | 0.78 | EPHX2 (0.77) | EPHX2ALDH1A1NAMPTCYP2C9CYP2C19 | |
| SCHEMBL30441052 | 0.77 | EPHX2 (0.67) | EPHX2ALDH1A1NAMPTPOLBKDM4E | |
| SCHEMBL31710264 | 0.77 | KMT2A (0.69) | EPHX2POLBCYP2C9CYP2C19EPHX1 | |
| SCHEMBL31717905 | 0.76 | EPHX2 (0.66) | EPHX2POLBCYP2C9CYP2C19EPHX1 | |
| SCHEMBL13739448 | 0.75 | EPHX2 (0.68) | EPHX2POLBCYP2C9CYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885ALDH1A1 385/4885HRH3 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.